NLRC5 germline variants as potential pharmacogenomic markers for immune checkpoint inhibitors 🔗 Access full article via Journal for ImmunoTherapy of CancerShare:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
